Profound Medical Corp (PROF)

Profound Medical Corp.'s stock price has been impacted by several events in the past six months. The company missed revenue expectations in Q4 2025, leading to a stock price decline. The CAPTAIN trial met its primary safety endpoint, showing superior outcomes for TULSA. TULSA-PRO achieved milestones, including Texas Prostate completing its 100th procedure and an installed base reaching 78 systems. In December 2025, the company announced expected funding and filed a follow-on equity offering. In May 2026, Profound Medical reported strong first-quarter 2026 financial results, with revenue up 104% year-over-year, and announced Humana coverage for the TULSA Procedure. Despite beating Q1 2026 earnings per share and revenue estimates, the stock experienced a slight decrease on May 8, 2026.

The provided information does not contain explicit details regarding demand seasonality for Profound Medical Corp.'s products and services. The company generates revenue from both capital equipment sales and recurring sales of single-use devices and related services, which could suggest a more consistent demand for the recurring revenue stream.

Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapeutic systems for tissue ablation. Its flagship product, TULSA-PRO, integrates real-time MRI, AI, robotic ultrasound, and temperature feedback for prostate tissue ablation. TULSA-PRO is used for various prostate conditions, including prostate cancer and benign prostatic hyperplasia. The company also commercializes Sonalleve, a therapeutic platform for non-invasive ablation, approved for treating uterine fibroids and other conditions. Profound Medical generates revenue through capital equipment sales and recurring sales of single-use devices and services.

Profound Medical Corp. is incorporated in Ontario, Canada, with its corporate office in Mississauga. The company operates and markets its products in Canada, the United States, Germany, Finland, and China. It has distribution agreements for TULSA-PRO and Sonalleve in regions including Canada, Saudi Arabia, Australia, and New Zealand. Sonalleve is primarily marketed in European and Asian markets.

Profound Medical Corp.'s brand reputation has been positively influenced by the successful CAPTAIN trial, demonstrating TULSA-PRO's safety and efficacy. The increasing number of TULSA-PRO installations and its adoption by prestigious institutions enhance the company's standing. The company was honored with INOVAIT's Mount Logan Award for the TULSA Procedure. The celebration of 500 Sonalleve procedures highlights the expansion of incision-free care in women's health, contributing positively to its reputation.

Profound Medical Corp. has significant institutional ownership, with 65 institutional owners holding 15,280,018 shares. Major institutional owners include FIL Ltd, Gagnon Securities LLC, and Rosalind Advisors Inc. Arun Swarup Menawat is a significant individual shareholder, owning 587,089 shares, representing 1.62% of the company.